Daily Digest — October 6, 2026

Just filed

Lycia Therapeutics (LYCA)

LYCA · Initial S-1 · terms not yet set · biopharma · platform play

Lycia is a clinical-stage biotech built around Nobel laureate Carolyn Bertozzi's LYTAC technology — a platform for degrading extracellular proteins that PROTACs and molecular glue degraders cannot reach. The lead program, LCA-0061, is an anti-IgE cataLYTAC conjugate in Phase 1, targeting food allergy and Graves' disease. The early data are notable: mean maximum IgE reduction of 96% in the first cohort, with 95% of subjects sustaining that reduction at 28 days post-dose. Whether that translates through later-stage trials is the entire question, but the Phase 1 signal is clean enough to justify the filing.

The financials are what you'd expect from a pre-commercial platform company. The most recent fiscal year showed collaboration revenue of $14.9 million — up from $6.7 million the year prior — with a net loss of $26.5 million. Through the first half of this year, the company recognized $2.3 million in collaboration revenue and spent $25.8 million on R&D. Cash on hand stands at $148.1 million against an accumulated deficit of $136.8 million, on $266.6 million raised since founding in 2019. Terms are not yet set. The markets the filing cites — food allergy (projected at $15 billion globally) and Graves' disease (projected at $7 billion globally by 2032) — are real and underserved. The thesis here is the platform, not the pipeline: if LYTAC degradation proves durably superior to what existing anti-IgE therapies already deliver, there is a meaningful story; if it does not, the market size projections are beside the point.

---

New Iceland Arctic Acquisition Corp.

No ticker yet · Initial S-1 · filed to raise up to $115 million · SPAC · Iceland/Arctic focus

New Iceland Arctic Acquisition is a blank-check company targeting businesses in Iceland and the broader Arctic region. The trust holds $100 million at base (up to $115 million if the 45-day greenshoe is fully exercised), priced at $10 per unit. The geographic pitch: the filing cites an estimated $1 trillion in Arctic infrastructure investment underway, with quality regional businesses that lack ready U.S. capital market access. The combination deadline is 365 days from IPO.

The structure carries the tensions standard to this vehicle, and they're worth tracking clearly. The sponsor paid $25,000 in aggregate for founder shares that represent 24% of post-IPO equity — an asymmetry that sharply concentrates the incentive to complete a deal over finding the right one within the 12-month window. The filing's own dilution table puts implied value per share at combination at $7.18, against the $10 offer price — structural dilution of 28.2% before any target is named. Trust is held at $10.00 per share with standard redemption rights for public holders, but Class B shares (founder shares) carry 10 votes per share against Class A's 1, concentrating deal-approval power decisively with the sponsor. The geography thesis is real; the structural math deserves as much attention as the Arctic narrative.